In the United States clinical trials commenced only in 2008 . based on three 12-month clinical trials, the US Food and Drug Administration approved riboflavin ophthalmic solution and KXL system for crosslinking on April 18, 2016, for the treatment of progressive keratoconus, and on July 19, 2016, for corneal ectasia after refractive surgery, making them the first FDA approved treatment for keratoconus and post-LASIK ectasia.
42.
In the United States clinical trials commenced only in 2008 . based on three 12-month clinical trials, the US Food and Drug Administration approved riboflavin ophthalmic solution and KXL system for crosslinking on April 18, 2016, for the treatment of progressive keratoconus, and on July 19, 2016, for corneal ectasia after refractive surgery, making them the first FDA approved treatment for keratoconus and post-LASIK ectasia.
